References
- Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425–456.
- Wang P, Koyama Y, Liu X, et al. Promising therapy candidates for liver fibrosis. Front Physiol 2016;7:47.
- Toosi AE. Liver fibrosis: causes and methods of assessment, a review. Rom J Intern Med 2015;53:304–314.
- Liu T, Zhou Y, Ko KS, Yang H. Interactions between Myc and mediators of inflammation in chronic liver diseases. Mediators Inflamm 2015;2015:276850.
- Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006;10:76–99.
- van Dijk F, Olinga P, Poelstra K, Beljaars L. Targeted therapies in liver fibrosis: combining the best parts of platelet-derived growth factor BB and interferon gamma. Front Med (Lausanne) 2015;2:72.
- Shaker ME, Salem HA, Shiha GE, Ibrahim TM. Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression. Fundam Clin Pharmacol 2011;25:248–257.
- Shaker ME, Shiha GE, Ibrahim TM. Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis. Eur J Pharmacol 2011;670:593–600.
- Shiha GE, Abu-Elsaad NM, Zalata KR, Ibrahim TM. Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: an insight. Clin Exp Pharmacol Physiol 2014;41:788–797.
- Skhirtladze C, Distler O, Dees C, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008;58:1475–1484.
- Yokota A, Kimura S. Novel agents to override imatinib resistance mechanisms. Drug Develop Res 2008;69:398–406.
- Dos Santos C, McDonald T, Ho YW, et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood 2013;122:1900–1913.
- Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214–2214.
- Gaki GS, Papavassiliou AG. Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease. Neuromolecular Med 2014;16:217–230.
- Jamali AE, Valente AJ, Lechleiter JD, et al. novel redox-dependent regulation of nox5 by the tyrosine kinase c-abl. Free Radic Biol Med 2008;44:868–881.
- Liang S, Kisseleva T, Brenner DA. The role of NADPH oxidases (NOXs) in liver fibrosis and the activation of myofibroblasts. Front Physiol 2016;7:17.
- Bhattacharyya S, Chen SJ, Wu M, et al. Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol 2008;173:1085–1099.
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
- Hadwan MH, Abed HN. Data supporting the spectrophotometric method for the estimation of catalase activity. Data Brief 2016;6:194–199.
- Yagi K. Assay for blood plasma or serum. Methods Enzymol 1984;105:328–331.
- Hu ML. Measurement of protein thiol groups and glutathione in plasma. Meth Enzymol 1994;233:380–385.
- Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996;29:225–229.
- Özden H, Bildirici K, Üstüner D, Üstüner C, Cengiz BP, Tülay A, et al. Histopathologic examination of rat liver after experimental application of fluoxetine. Türkiye Ekopatoloji Dergisi 2005;11:9–15.
- Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–699.
- Rio DC, Ares M Jr, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc 2010;2010:pdb prot5439.
- Almeda-Valdes P, Aguilar Olivos NE, Barranco-Fragoso B, et al. The role of dendritic cells in fibrosis progression in nonalcoholic fatty liver disease. Biomed Res Int 2015;2015:768071.
- Pierce RA, Glaug MR, Greco RS, et al. Increased procollagen mRNA levels in carbon tetrachloride-induced liver fibrosis in rats. J Biol Chem 1987;262:1652–1658.
- Bala A, Haldar PK, Kar B, et al. Carbon tetrachloride: a hepatotoxin causes oxidative stress in murine peritoneal macrophage and peripheral blood lymphocyte cells. Immunopharmacol Immunotoxicol 2012;34:157–162.
- Chiu HW, Hua KF. Hepatoprotective effect of wheat-based solid-state fermented Antrodia cinnamomea in carbon tetrachloride-induced liver injury in rat. PLoS One 2016;11:e0153087.
- Chen X, Ying X, Chen L, et al. Protective effects of sesamin on liver fibrosis through antioxidative and anti-inflammatory activities in rats. Immunopharmacol Immunotoxicol 2015;37:465–472.
- Soni B, Visavadiya NP, Madamwar D. Ameliorative action of cyanobacterial phycoerythrin on CCl(4)-induced toxicity in rats. Toxicology 2008;248:59–65.
- Khan RA, Khan MR, Ahmed M, et al. Hepatoprotection with a chloroform extract of Launaea procumbens against CCl4-induced injuries in rats. BMC Complement Altern Med 2012;12:114.
- Ge H, Zhao M, Lee S, Xu Z. Mitochondrial Src tyrosine kinase plays a role in the cardioprotective effect of ischemic preconditioning by modulating complex I activity and mitochondrial ROS generation. Free Radic Res 2015;49:1210–1217.
- Amiri I, Karimi J, Piri H, et al. Association between nitric oxide and 8-hydroxydeoxyguanosine levels in semen of diabetic men. Syst Biol Reprod Med 2011;57:292–295.
- Bokhari J, Khan MR. Evaluation of anti-asthmatic and antioxidant potential of Boerhavia procumbens in toluene diisocyanate (TDI) treated rats. J Ethnopharmacol 2015;172:377–385.
- Giannoni E, Buricchi F, Raugei G, et al. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol 2005;25:6391–6403.
- Samarakoon R, Overstreet JM, Higgins PJ. TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal 2013;25:2648.
- Cruz FF, Horta LF, Maia Lde A, et al. Dasatinib reduces lung inflammation and fibrosis in acute experimental silicosis. PLoS One 2016;11:e0147005.
- Yilmaz O, Oztay F, Kayalar O. Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice. Growth Factors 2015;33:366–375.
- Fraser CK, Lousberg EL, Kumar R, et al. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol 2009;37:1435–1444.
- Morton JP, Karim SA, Graham K, et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2010;139:292–303.
- Liu Y, Wang Z, Kwong SQ, et al. Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 2011;55:612–625.
- Wang L, Christopher LJ, Cui D, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 2008;36:1828–1839.
- Xue T, Luo P, Zhu H, et al. Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes. Toxicol Appl Pharmacol 2012;261:280–291.